Tesis sobre el tema "Adjuvant"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores tesis para su investigación sobre el tema "Adjuvant".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore tesis sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
CIRELLI, ELISA. "Co-adjuvant effect of retinoic acid in combination with systemic adjuvants on mucosal vaccine immunization". Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2014. http://hdl.handle.net/2108/203188.
Texto completoThe vast majority of pathogens invade the host through or cause disease at mucosal surfaces. Development of novel immunization strategies suitable for mucosal vaccines is widely desired to protect against infectious diseases. However, very few mucosal vaccines are available for human use, none of which are recombinant proteins or subunits of pathogens, owing to the lack of potent and safe mucosal adjuvants. Given the crucial role of Vitamin A metabolites, such as retinoic acid (RA) in imprinting a mucosal homing capacity on T and B cells, as well as its potential to promote the differentiation of IgA-producing plasma cells, RA holds potential as a candidate molecule to improve mucosal vaccinations. In this study, we investigated new strategies of immunization to amplify both systemic and mucosal immune responses by administering RA. First, we observed that treatment with RA synergises with the adjuvant capacity of cholera toxin (CT) to enhance both systemic and mucosal Ag-specific immune responses. The combination of mucosal priming with Ag alone, followed by a boost with systemic adjuvant was also evaluated. Mice treated with RA showed a higher titer of mucosal IgA compared to untreated mice, after intranasal priming with Ag followed by a systemic boost with Ag plus Alum. After eight months, higher IgG Ag-specific antibodies in the serum and a higher frequency of Ag-specific IgG and IgA secreting cells were detected in the bone marrow of mice treated with RA as compared to untreated mice. Higher percentages of proliferating CD4 and CD8 T cells upon Ag stimulation were found in the spleens, in the mesenteric lymph nodes and in the colonic lamina propria of mice treated with RA. Next, we evaluated the effects of RA on systemic vaccination with a subunit vaccine against tuberculosis. This vaccine includes CAF01 as adjuvant and the mycobacterial derived fusion protein H56. We found that mice treated with RA as compared with untreated ones, showed enhanced mucosal (IgA) H56 mycobacterial fusion proteinspecific antibody responses and enhanced Ag-specific CD4+ T lymphocytes harbouring the lung after systemic immunization with the TB subunit vaccine. Therefore, we evaluated the effects of RA on protection against challenge with virulent Mycobacterium tuberculosis (Mtb) strain after systemic vaccination with the TB subunits vaccine (CAF01 and H56). Vaccination with BCG was included in the experiment as control. We found that immunization with CAF01 and H56 in presence of RA leads to a lower bacterial colonization in the lungs 14 days after challenge as compared to control mice. Furthermore, higher pro-inflammatory cytokine production, such as IFNγ and IL-17 was found in the lung of mice immunized with CAF01 and H56 in presence of RA 24h after Mtb infection. Therefore, we hypothesize that the mucosal immune responses elicited during vaccination in presence of RA could have an impact on the containment of bacterial growth in the lungs. This approach can contribute to progress beyond the state of the art in adjuvant research by achieving mucosal immunity in the absence of mucosal adjuvants.
Critchley, P. H. S. "Adjuvant therapy in Parkinson's disease". Thesis, University of Cambridge, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.598153.
Texto completoTigno-Aranjuez, Justine Daphne Tiglao. "Adjuvant Guided T cell Responses". Case Western Reserve University School of Graduate Studies / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=case1244035297.
Texto completoFasquelle, François. "Etude de la délivrance d’antigènes dans les voies aériennes en utilisant des nanoparticules de maltodextrine lipidées". Thesis, Lille, 2020. https://pepite-depot.univ-lille.fr/LIBRE/EDBSL/2020/2020LILUS024.pdf.
Texto completoThe mucosal routes of immunization present several advantages compared to classical injection routes. Indeed, besides a better compliance towards patients, these routes possess their own immune system, also known as the Mucosal Associated Lymphoid Tissue (MALT), able to trigger a local mucosal response after immunization. This tissue is mainly located in the nasal and intestinal mucosa, where it is spread in small extents called Follicular Associated Epithelium (FAE). On their apical surface, the FAE contain specialized epithelial microfold cells (or M cells), whose role is to survey potential infections by sampling pathogenic fragments, and which overlay a lymphocyte and antigen presenting cells (APC) zone. Then, when an infection occurs, M cells sample and translocate antigenic fragments to CPA, which could therefore trigger lymphocyte maturation and the initiation of the subsequent immune response. This activation will lead to both humoral and cellular immunity in the infected epithelium and could also spread to distant mucosa. As many pathogens infect the body through mucosa, this way of immunization is often considered.Adjuvants are frequently added to subunit vaccines to enhance their immunogenicity toward APC. Indeed, despite their lower toxicity, they are also less immunogenic than live-attenuated vaccines. However, the administration of classical adjuvanting molecules, such as toxins or immunostimulating emulsions, via mucosal routes, has often led to serious adverse effects. Therefore, the alternative use of delivery systems to deliver antigen in APC after mucosal administration is more and more studied.Antigen delivery systems include immunomodulating particles, and inert delivery systems. The first ones can enhance the mucosal antigen bioavailability by vectorizing antigens to APC, and at the same time trigger intracellular pro-inflammatory pathways, to drive the Th1/Th2 immune balance. Among them, virus-like particles (VLP), saponin-based emulsions (ISCOMs) or MPL-containing liposomes are the most represented in clinical trials. However, their mucosal administration can lead to the same adverse effects than classical immunostimulating molecules. In parallel, true delivery systems can enhance the antigens immunogenicity by increasing their intracellular delivery, thus mimicking a natural infection. They are therefore far less toxic for the mucosa than immunomodulating particles but need to be more efficient in the mucus penetration, in the antigen association and in the APC intracellular delivery.During this thesis, we deciphered the mechanisms allowing cationic and lipidated maltodextrine nanoparticles (NPL) to deliver antigens after nasal administration.We first evaluated the ability of NPL to cross the airway mucus barrier, compared to mucopenetrant particles (PEG-coated PLGA or PLGA-PEG) and mucoadherent particles (chitosan-coated PLGA or PLGA-CS), by measuring their displacement in reconstituted mucus. We observed that in presence of the phospholipid core, the NPL were able to move in the mucus, while PLGA-CS NPs remained stuck in the gel. Moreover, we observed that the NPL uptake and the protein delivery in airway epithelial cells were not impaired by the presence of mucins, contrary to PLGA-CS that were hindered by the mucins, and to PLGA-PEG which were not taken up by the cells, due to their neutral surface charge. We finally demonstrated that the NPL mucopenetration was allowed thanks to steric and repulsive electrostatic forces between the anionic phospholipid core and the mucins.In parallel, we studied the mechanisms allowing the NPL to enhance the immunogenicity of subunit antigens after nasal administration, with a highlight on the importance of the NP’s density [...]
Holm, Barbro. "Pathogenetic studies of adjuvant-induced arthritis /". Stockholm, 2002. http://diss.kib.ki.se/2002/91-7349-347-3/.
Texto completoKrashias, George. "Adjuvant for vaccination against HIV-1". Thesis, University of Oxford, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.531970.
Texto completoMorton, Dion. "Adjuvant screening in familial adenomatous polyposis". Thesis, University of Bristol, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.260328.
Texto completoRathbone, Emma Jane. "Adjuvant bisphosphonates in early breast cancer". Thesis, University of Leeds, 2018. http://etheses.whiterose.ac.uk/22679/.
Texto completoKho, Sunn Sunn Patricia. "Optimising Adjuvant Treatment for Colorectal Cancer". Thesis, The University of Sydney, 2013. http://hdl.handle.net/2123/9470.
Texto completoFreitas, Fabio Alessandro de. "Avaliação de adjuvantes como estratégia para aumentar a produção da vacina influenza no Instituto Butantan". Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/46/46137/tde-29092015-121836/.
Texto completoInfluenza, also known as flu, is a viral infectious disease that infects a large number of people annually, being responsible by large morbidity and mortality rates. The etiologic agent is the Myxovirus influenzae, an enveloped virus with single-stranded RNA and negative polarity. Vaccination is the best way to prevent the virus infection; however, the production capacity of this vaccine is not sufficient to vaccinate the entire world population, especially in cases of pandemics. This project aimed to develop an adjuvanted influenza vaccine (split and inactivated), increasing the productive capacity of this vaccine in Instituto Butantan, which is estimated in approximately 40 million of doses by campaign. Influenza vaccines formulated with adjuvants can produce the same protective immunological response against the virus using less amount of antigen increasing the production capacity of this vaccine up to four times. Twenty-three adjuvants containing fat-soluble vitamins (vitamins A, D and E), vitamin B2 (water-soluble vitamin), MPLA (monophosphoryl lipid A, produced by Instituto Butantan as a byproduct of pertussis low vaccine production) and aluminum hydroxide gel were studied. An adjuvant similar to MF59® (Novartis adjuvant) containing squalene was used as control. The immune response elicited in BALB/c mice after immunization with the different formulations of the influenza vaccine and the existence or not of toxicity induced by the vaccines formulations were studied. The most promising formulation will be part of the candidate formulations of clinicai trials. The animais received the vaccine formulations intraperitoneally and at specific days blood samples were taken to serological tests (hemagglutination inhibition and ELISA). At the end, they were euthanized to collect the spleens and splenic cells were cultivated to evaluate cytokines by flow cytometry: IL-2, IL-4, IL-6, IL-10, IL-17 TNF-α and INF-γ. Furthermore, in one experiment the immunological memory against influenza was evaluated, an important parameter to vaccines. The most promising formulations contained besides to alum either B. pertussis MPLA or B2 vitamin. Tocopherol (vitamin E) presented good results too, however it has a potential relationship with reported cases of narcolepsy. The memory test was able to demonstrate that these formulations induced long lasting immune memory response. Thus, these are promising results for new pre-clinical and clinical trials with seasonal trivalent influenza vaccine (split and inactivated).
Carvalho, Marnen Almeida. "Avaliação do uso de óleos de origem vegetal para formulação de adjuvantes vacinais". Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/9/9134/tde-29092015-082417/.
Texto completoVegetable oils are renewable raw materials. These substances are metabolizable, biodegradable, of easy availability and low cost. The need for safe vaccine adjuvants that can modulate the Th1/Th2 immune response drives the search for new substances with similar behavior. This study aims to evaluate and identify a vegetable oil able to mimic the adjuvant action of the mineral oils used commercially, and modulate the immune response. There were performed tests of in vivo acute toxicity, emulsion formation, stability, quality and immunogenicity with formulations with rabies virus. Some formulations derived from the sunflower, canola and buriti oils proved to be non-toxic, stable and of good quality. Groups of mice inoculated with these formulations had immune responses supporting their adjuvant capacity, not differing significantly (p <0.05) from the results of the commercial mineral oil. It was concluded that it is possible to prepare stable non-toxic emulsions from vegetable oils to be used as vaccine adjuvants and vehicles. Vaccine formulations as emulsions from vegetable oil, composed mostly by the oils of sunflower and canola had adjuvant activity and potency similar to and as effective as the mineral oil. The vegetable oils should be in its raw state or semi refined, without the addition of antioxidants and preservatives. Finally, there seems to be a tendency to balance Th1/Th2 response by formulations with vegetable oils.
Ferrari, Analy Ramos Mendes. "Efeitos da quimioterapia metronômica sobre angiogênese e linfangiogênese de carcinomas mamários de cadelas. /". Araçatuba, 2019. http://hdl.handle.net/11449/182182.
Texto completoResumo: Nas últimas décadas biomarcadores de angiogênese e linfangiogênese tumoral são alvos de estudos e, em humanos, estes aspectos da vasculatura tumoral já são utilizados como fatores prognósticos em neoplasias mamárias. Em cadelas não há estudos suficientes para demonstrar o significado clínico-patológico da linfangiogênese em neoplasias mamárias. De maneira similar, não há estudos que demonstrem efeitos antilinfangiogênicos de terapias como a quimioterapia metronômica (QM), classicamente caracterizada como uma terapia antiangiogênica. Este estudo teve como objetivos estabelecer os efeitos da QM na angiogênese e linfangiogênese tumoral destas neoplasias, assim como obter o significado clínico-patológico da densidade de vasos linfáticos em neoplasias mamárias caninas. Foram utilizadas 40 cadelas portadoras de carcinomas mamários, divididas em dois grupos, sendo um tratado somente com mastectomia e outro tratado com quimioterapia metronômica (QM) seguida de mastectomia. A biópsia do linfonodo sentinela foi preconizada para estabelecimento do “status” do tecido linfoide sentinela. Após, foi realizada a classificação e graduação histopatológica das neoplasias, e procedeu-se a imunomarcação para determinar a densidade de vasos linfáticos (DVL), a densidade microvascular (DMV), índice de proliferação celular (IP), índice apoptótico (IA), escore de COX-2, grau do fator de crescimento endotelial vascular (VEGF) e metástase nodal. As imunomarcações foram comparadas entre os grupos e a DV... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: In recent decades biomarkers of tumor angiogenesis and lymphangiogenesis have been studied and, in humans, these aspects of tumor vasculature are already used as prognostic factors in breast cancer. In bitches there are no studies that prove the clinicopathological significance of lymphangiogenesis in mammary neoplasms. Similarly, there are no studies demonstrating anti-lymphangiogenic effects of therapies such as metronomic chemotherapy (MC), classically characterized as anti-angiogenic therapy. This study aimed to establish the effects of MC on tumor angiogenesis and lymphangiogenesis of these neoplasms, as well as to obtain the clinical-pathological significance of lymphatic vessel density in canine mammary tumors. Forty bitches with mammary carcinomas were used, divided into two groups, one treated with mastectomy and the other treated with MC followed by mastectomy. Sentinel lymph node biopsy was recommended for establishing the status of the sentinel lymph node. Afterwards, classification and histopathological graduation of the neoplasms was performed, followed by immunostaining and determination of lymphatic vessel density (LVD), microvascular density (MVD), cell proliferation index (PI), apoptotic index (AI), COX-2 score, and vascular endothelial growth factor (VEGF) grade. Immunostain were compared between the groups and the LVD compared to clinicopathological aspects. Antiangiogenic and pro-apoptotic effects were observed in the group treated with MC, but without an... (Complete abstract click electronic access below)
Doutor
Stertman, Linda. "Starch Microparticles as an Oral Vaccine Adjuvant with Emphasis on the Differentiation of the Immune Response". Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ-.bibl. [distributör], 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4680.
Texto completoWirth, Manfred P. y Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer". Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133839.
Texto completoTye, Gee Jun. "Combined adjuvant for stimulation of cellular immunity". Thesis, King's College London (University of London), 2012. https://kclpure.kcl.ac.uk/portal/en/theses/combined-adjuvant-for-stimulation-of-cellular-immunity(b1be07ae-b8d4-40a8-9258-bc3e3413df9d).html.
Texto completoWirth, Manfred P. y Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer". Karger, 2002. https://tud.qucosa.de/id/qucosa%3A27540.
Texto completoDewar, John Barr. "A novel adjuvant : polymerised serum albumin beads". Thesis, Rhodes University, 1985. http://hdl.handle.net/10962/d1011146.
Texto completoSmeenk, Henri Gerard. "Surgical and adjuvant treatment of pancreatic cancer". [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2008. http://hdl.handle.net/1765/13713.
Texto completoDodds, Darrin Matthew. "Adjuvant effects on herbicide absorption and translocation". Diss., Mississippi State : Mississippi State University, 2007. http://library.msstate.edu/etd/show.asp?etd=etd-11022007-143506.
Texto completoBossaer, John B. y Christian M. Thomas. "Adjuvant Treatment of Newly Diagnosed Breast Cancer". Digital Commons @ East Tennessee State University, 2011. https://dc.etsu.edu/etsu-works/2313.
Texto completoDubois, Natasha. "Caractérisation de la réponse immune induite par un adjuvant comprenant un agoniste du TLR4 dans des modèles murins". Thesis, Université Paris-Saclay (ComUE), 2016. http://www.theses.fr/2016SACLS131/document.
Texto completoIn 2014 tuberculosis (TB) surpassed HIV as the leading cause of death by an infectious disease worldwide emphasizing the urgent need to develop a more effective vaccine against this airborne disease. The Infectious Disease Research Institute (IDRI) TB candidate vaccine ID93/GLA-SE is currently undergoing a Phase IIa clinical trial and has shown promising preclinical and clinical results. In murine models of TB this vaccine drives a strong CD4 TH1 response, which is thought to be important for protection against TB, and an IgG2c skewed B cell response. However, little is known about the cellular and molecular events that drive GLA-SE adjuvanticity.To that end, the main objective of my thesis was to elucidate the key mechanisms that connect innate and adaptive immune responses elicited by this adjuvant in the murine model. A secondary objective was to evaluate the possibility of using ID93/GLA-SE as adjunct therapy to existing antibiotic treatments to reduce relapse rates after TB treatment.Collectively the results obtained during this research project and thesis broaden our knowledge and our current understanding of the mechanisms involved in the adaptive immune response induced by GLA-SE and show the capacity of ID93/GLA-SE to be used as a therapeutic vaccine against TB to reduce post-therapeutic relapse rates
Baalbaki, Moussa. "Influence des interactions du couple ciment/adjuvant dispersant sur les propriétés des bétons importance du mode d'introduction des adjuvants". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape11/PQDD_0005/NQ40507.pdf.
Texto completoBaalbaki, Moussa. "Influence des interactions du couple ciment/adjuvant dispersant sur les propriétés des bétons : importance du mode d'introduction des adjuvants". Sherbrooke : Université de Sherbrooke, 1998.
Buscar texto completoBachega, Tiago Furtado [UNESP]. "Lixiviação de sulfentrazone e amicarbazone com adição de óleo em resposta à precipitação e emergência de Ipomea spp. em função da profundidade de semeadura e cobertura com palha". Universidade Estadual Paulista (UNESP), 2008. http://hdl.handle.net/11449/96990.
Texto completoFunep
O presente trabalho objetivou avaliar a lixiviação dos herbicidas sulfentrazone e amicarbazone aplicados a campo, com e sem óleo mineral, e correlacioná-la com o controle de corda-de-viola (Ipomoea nil e I. hederifolia), oriundas de sementes depositadas em diferentes profundidades e sob diferentes camadas de palha de cana-de-açúcar. Em área de plantio de canade- açúcar, após acumuladas precipitações de 35, 67 e 106 mm, tubos de PVC de 10 cm de diâmetro, seccionados longitudinalmente, foram enterrados até a profundidade de 35 cm. Os tubos foram retirados e, depois da última amostragem (106 mm), foram semeadas as plantas testes sorgo e Ipomoea nil em toda a seção dos tubos. Foram realizadas avaliações visuais de intoxicação aos 7, 10 e 15 dias após a semeadura (DAS) e aos 20 DAS procedeu-se a determinação da matéria seca das plântulas. O delineamento experimental utilizado foi o de blocos ao acaso, em esquema de parcelas subdivididas com quatro repetições. As parcelas consistiram da aplicação de dois herbicidas (amicarbazone e sulfentrazone), adicionados ou não de óleo, e uma testemunha sem herbicida. Nas subparcelas estudou-se as profundidades de lixiviação (0,0-2,5; 2,5-5,0; 5,0-10; 10-15; 15-20; 20-25; 25-30; 30-35 cm). Pelo bioensaio, a presença do sulfentrazone foi estimada na camada superior até os 10 cm de profundidade, mesmo com 106 mm de precipitação e independentemente da adição do óleo.
This study aimed to evaluate the lixiviation of sulfentrazone and amicarbazone applied to the field, with and without mineral oil, and its relationship with the control of morning glory (Ipomoea nil and I. hederifolia), from seed deposited at different depths and under different layers of sugar cane straw. In sugar cane field, after accumulated rainfall of 35, 67 and 106 mm, PVC pipes of 10 cm in diameter, sliced lengthwise, were buried by the depth of 35 cm. The tubes were removed and, after the last sampling (106 mm), the tests plants sorghum and Ipomoea nil were sown across the section of pipe. Visual assessments of intoxication were made at 7, 10 and 15 days after sowing (DAS) and 20 DAS the dry weight of the seedlings was determined. The experimental design was a randomized block in split plots scheme with four replications. The plot consisted of application of two herbicides (amicarbazone and sulfentrazone), with or without mineral oil, and a control without herbicide. In subplots was studied the depths of leaching (0,0-2,5; 2,5-5,0; 5,0-10, 10-15, 15-20, 20-25; 25-30; 30 - 35 cm). For the bioassay, the presence of sulfentrazone was estimated in the upper layer to the 10 cm deep, even with 106 mm of rainfall and whether adding the oil.
Lazaroto, Juliana. "Desenvolvimento de protótipo de vacina contra Pasteurella multocida sorotipo A em suínos". Universidade do Estado de Santa Catarina, 2015. http://tede.udesc.br/handle/handle/945.
Texto completoFor a long time, Pasterella multocida has been considered only as a secondary agent in pneumonias in swine. However, studies developed in Brazil identified different isolates of P. multocida able to operate as primary disease agent in swine. The objective of his project was to study protection aspects of a vaccine with pathogenic samples of P. multocida in experimental model with high sanity status pigs. In addition, it aims to describe the expression of immune response in swine induced by P. multocida infection, and determinate the prevalence of P. multocida in tonsils of vaccinated and not vaccinated pigs through immunohistochemistry. The study was divided into three experiments: Immunization of mice with vaccines prepared with different adjuvants , Test of two adjuvants used in vaccine with a P. multocida homologous strain in swine and Experimental challenge in swine with a P. multocida heterologous strain to the vaccine . Four adjuvants were tested in mice: Al(OH)3, ISA 206, Montanide GEL 01 and ISA 760. Two of them were selected for testing in swine: Al(OH)3 which showed better results in mice-, and ISA 760 for being an oily adjuvant. At the second experiment, although two vaccines have been effective in the disease protection, the one with the adjuvant Al(OH)3 was selected, because showed lower vaccine reaction. Eighteen pigs were distributed into three groups for the specific test of the vaccine for pathogenic samples of P. multocida. Group 1 (G1) vaccine with Al(OH)3; group 2 (G2) infection control; and group 3 (G3) negative control. After the experiment, the animals were euthanized, and samples were collected in ice - for microbiological cultivation and relative quantification of cytokines gene expression (IL1 β, IL2, TNFα) and TLR4 , and in formaldehyde, for routine histopathology and immunohistochemistry. Results showed that the vaccine prototype with adjuvant Al(OH)3 was efficient in controlling pulmonary pasteurellosis. The immune response was mediated by TLR4, with increased expression of TNFα. IL-1β and IL2 were also expressed, however, there was no significant difference between the groups. The immunostaining of P. multocida in tonsil was positive in all pigs challenged with the bacteria
Por muito tempo, Pasteurella multocida foi considerada apenas como agente secundário nas pneumonias em suínos, todavia, estudos realizados no Brasil identificaram diferentes isolados de P. multocida capazes de atuar como agente primário de doença em suínos. Esse projeto teve como objetivo estudar aspectos de proteção de uma vacina com amostras patogênicas da P. multocida em modelo experimental com suínos de alto status sanitário . E de forma paralela descrever expressão da resposta imune dos suínos induzida pela infecção da P. multocida e determinar a prevalência dessa bactéria em tonsilas de suínos vacinados e não vacinados através de imunohistoquímica. O trabalho foi dividido em três experimentos: Imunização de camundongos com vacinas preparadas com diferentes adjuvantes ; Teste de dois adjuvantes utilizados na vacinação de suínos frente ao desafio com uma cepa homóloga de P. multocida ; e Desafio experimental em suínos com uma cepa de P. multocida heteróloga à da vacina . Em camundongo foram testados quatro adjuvantes: Al(OH)3, ISA 206, Montanide GEL 01 e ISA 760, dos quais, foram selecionados dois para teste em suínos: Al(OH)3, que apresentou melhor resultado nos camundongos e ISA 760, por ser um adjuvante oleoso. Embora as duas vacinas tenham sido efetivas na proteção da doença, no segundo experimento, selecionou-se àquela com adjuvante Al(OH)3, que apresentou menor reação vacinal. No terceiro experimento realizado em suínos, foram utilizados 18 suínos em três grupos: grupo 1 (G1) - vacina com Al(OH)3, e grupo 2 (G2) controle de infeção e grupo 3 (G3) controle negativo. Após o experimento os animais foram eutanasiados para avaliação patológica, coleta de amostras em gelo para cultivo microbiológico e quantificação relativa da expressão gênica das citocinas (IL1 β, IL2, TNFα) e TLR4, para histopatologia de rotina e imunohistoquimica. Os resultados demostraram que o protótipo de vacina com adjuvante Al(OH)3 foi eficiente no controle de pasteurelose pulmonar. O perfil da expressão da resposta imune foi mediado por TLR4, com aumento da expressão de TNFα. Também foram expressos IL-1β e IL2, porém sem diferença significativa entre os grupos. A imunomarcação de P. multocida na tonsila foi positiva em todos os suínos desafiados com a bactéria, independente de serem ou não vacinados
Roos, Maria y Anna Wilhelmsson. "Fysisk aktivitet hos kvinnor med bröstcancer som genomgår adjuvant cytostatikabehandling : Physical activity in women with breast cancer receiving adjuvant chemotherapy". Thesis, Örebro universitet, Institutionen för hälsovetenskap och medicin, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-29667.
Texto completoResearch has shown that physical activity improves survival for women diagnosed with breast cancer. Studies have also described that physical activity is a matter of importance for alleviating common side effects from chemotherapy which thereby increases the quality of life for these women. It has also emerged that there is insufficient information on this topic. As a first step, it is necessary to do a survey of the physical activity in women with breast cancer, their activity experiences and what importance physical activity play for them during adjuvant chemotherapy. This work was a cross-sectional study based on questionnaires. The purpose of this study was to describe physical activity in women with breast cancer receiving adjuvant chemotherapy. 30 women who received adjuvant chemotherapy at the medical treatment unit for oncology at Örebro University Hospital (USÖ) answered the questionnaire. The questionnaire contained both closed and open-ended questions. The data was analysed with descriptive statistics. The final open-ended questions were analysed with a modified manifest content analysis. The result showed that the women had the same activity level before as during the treatment period. The reasons for the women to be physically active were to decrease fatigue and to divert their minds. The majority of the women experienced feeling psychologically better and experienced better recovery between chemotherapy treatments. Walking was the most frequently used activity. The majority of the women received information about physical activity, but less than half of the women were followed-up. This information was primarily given by nurses and doctors.
Jansson, Åsa. "Immunologic and genetic studies of rat adjuvant-induced arthritis /". Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4323-0/.
Texto completoPelegrí, i. Gabaldà Carme. "Immunoteràpia de l'artritis adjuvant amb anticossos monoclonals antilimfocítics". Doctoral thesis, Universitat de Barcelona, 1995. http://hdl.handle.net/10803/1120.
Texto completoL'artritis adjuvant (AA) és una patologia induïda en rata que es considera model d'AR i que cursa amb inflor, eritema, dolor i impotència funcional de les articulacions dels animals afectats. Avui s'accepta que aquesta patologia és mitjançada fonamentaJment per limfòcits T.
En el present treball es va pretendre: identificar les poblacions cel.lulars presents en el teixit sinovial inflamat: esbrinar el possible paper dels limfòcits T gamma/delta, T CD4 i T CD8 en el desenvolupament i perpetuació de l'AA; i conèixer si la teràpia amb un anticòs monoclonal (AcMo) dirigit contra la molècula CD4 és capaç de modificar el curs de l'AA. Per assolir els objectius esmentats, és a dir, per delimitar quines subpoblacions de limfòcits T estan implicades en l'AA, es van realitzar diferents protocols d'immunoteràpia amb AcMo dirigits contra determinades molècules de superfície presents en els limfòcits T alfa/beta, T gamma/delta, T CD4 i T CD8.
Yoshino i col.laboradors, al 1990, ja van demostrar la implicació dels limfòcits T alfa/beta en el desenvolupament i en la perpetuació de l'AA, i en el present estudi el mateix AcMo R73 dirigit contra el TCR-alfa/beta de rata ha estat utilitzat com a control positiu de tractament. Fins a l'actualitat no es coneixia el paper dels limfòcits T gamma/delta a l'AA a causa de que no existia un AcMo anti-TCR-gamma/delta de rata. En el present treball, i gràcies al recent descobriment per part del grup del Prof. Hünig de Würzburg de l'AcMo V65 s'ha pogut avaluar la implicació d'aquestes cèl.lules en aquest model experimental. D'altra banda, també s'han realitzat estudis d'immunoteràpia emprant un AcMo anti-CD4. el W3/25, que no havia estat utilitzat anteriorment en l'AA, i que per tant, no es coneixia el seu potencial terapèutic en aquest model experimental. A més a més, s'ha assajat la teràpia combinada anti-CD4 + anti-CD8, que tampoc no ha estat descrita fins a l'actualitat, i que ha permès determinar els efectes de la població CD8+ sobre els Iimfbcits T CD4+-. Totes aquestes teràpies anaven encaminades a inhibir el desenvolupament de l'AA.
La inducció de l'AA en rates de la soca Wistar o Lewis es va realitzar mitjançant l'administració d'una suspensió de Mycobaeterium butyricum o de Mycobaeterium tuberculosis al 0,5% en vaselina liquida, per via intradèrmica a la base de la cua. Durant els primers dies després de la inducció no s'observa cap signe extern i a partir dels 10-12 dies es manifesta una.inflamació sistèmica que afecta a les extremitats posteriors i sovint també a les anteriors de l'animal. En els diferents experiments s'ha realitzat un seguiment de la inflamació dels animals mitjançant paràmetres clínics, com l'índex d'artritis, que comprèn la valoració clínica del grau d'eritema i d'edema de les quatre articulacions; i l'increment de volum articular de les extremitats posteriors, mesurat per pletismometria.
Per a l'anàlisi de les poblacions cel·lulars presents en teixit sinovial s'ha utilitzat una tècnica immunohistoquímica. Com a substrat s'han utilitzat talls criostàtics de membrana sinovial i la identificació de determinats antígens de membrana s'ha realitzat utilitzant AcMo dirigits contra aquests antígens de superfície cel·lular. La reacció s'ha revelat amb el mètode peroxidasa-anti-peroxidasa.
A partir de mostres de plasma dels animals artrítics. s'ha detenninat la concentració d'anticossos dirigits contra el micobacteri, la concentració dels AcMo administrats i de la resposta dirigida contra aquests, mitjançant tècniques d'ELISA.
Per a determinar l'efecte a nivell cel.lular dels AcMo administrats s'ha utilitzat la citometria de flux. Aquesta tècnica permet la identificació de poblacions cel.lulars mitjançant la detecció d'antígens de la seva superfície, prèviament marcats amb anticossos conjugats a un fluorocrom. Un pas previ per a l'anàlisi citomètrica de les poblacions de sang perifèrica és l'aïllament dels limfòcits. Amb el fi de conèixer quin mètode és el més adequat per analitzar els limtècits de sang perifèrica dels animals dels estudis d'immunoteràpia, es van comparar els efectes de quatre mètodes d'aïllament de limfòcits sobre sang de rata: gradient de Ficoll-Isopaque, lisi amb clorur amònic, lisi amb reactiu de Becton & Dickinson i lisi mitjançant el sistema Coulter Q-prep.
Els limfòcits es van marcar amb AcMo dirigits contra diferents subpoblacions limfocítiques. En considerar tots els marcatges realitzats no es van trobar diferències entre els mètodes, la qual cosa dona validesa als 4 mètodes per a sang de rata. Però l'anàlisi estadística que va considerar els resultats obtinguts per cada AcMo per separat va mostrar algunes diferències significatives. El gradient Ficoll-Isopaque, és el que va proporcionar uns percentatges més baixos de limfòcits CDS+, CD4+ i CD25+, suggerim una pèrdua selectiva d'alguns limfòcits T. Per altra banda, amb el clorur amònic, es van obtenir els percentatges més baixos de limfòcits B, i aquest fet es pot atribuir a que una part dels limfòcits B són sensibles a les condicions d'aquest mètode. En els dos mètodes comercials, els percentatges corresponents a la majoria de les poblacions estudiades van presentar valors intermitjos. En el nostre estudi, es va triar el clorur amònic com a mètode de lisi per els estudis d'immunoteràpia. Aquest mètode no afecta selectivament cap població de limfòcits T i, a més a més permet realitzar el marcatge sobre cèl.lules aïllades i presenta un baix cost.
Per conèixer quins tipus cel.lulars estan involucrats a nivell de l'articulació inflamada en l'AA, es va realitzar l'estudi histològic de la membrana sinovial de genoll. La membrana sinovial està formada per teixit conjuntiu i revesteix tota la cavitat articular, a excepció dels cartílags. El teixit sinovial artrític augmenta de mida i en general incrementa unes tres vegades el seu pes.
L'estudi histològic de la membrana sinovial mostra en el teixit control una capa íntima formada per 1 ó 2 fileres de sinoviòcits i una capa subíntima formada per teixit adipós amb alguns vasos sanguinis. Als 14 dies de la inducció, amb inflamació articular ja establerta, a nivell sinovial s'observa un augment en el nombre de fileres de cèl.lules de la capa íntima. També s'observen plegaments cap a la cavitat articular. Existeix un gran nombre de cèl.lules mononuclears i gran quantitat de fibres de col.làgen en la capa subíntima.
L'estudi immunohistoquímic de la membrana sinovial es va realitzar amb el mètode peroxidasa-antiperoxidasa. En alguns teixits sinovials inflamats, es van identificar algunes cèl.lules CD5+ amb l'AcMo OX19. Aquestes cèl.lules CD5+ no van aparèixer en cap teixit control sa. El nombre de cèl.lules CD8+ de la capa subíntima va incrementar significativament del dia 14 al 28 postinducció respecte als teixits control. L'AcMo W3/25, que s'uneix a l'antigen CD4 de limfòcits T col.laboradors i de macròfags, ja detecta cèl.lules positives en tots els teixits sinovials control i el seu nombre augmenta en els teixits artrítics. A causa de les poques cèl.lules CD5+ trobades i de la morfologia i la tinció citoplasmàtica d'aquestes cèl.lules es poden considerar macròfags. L'AcMo OX6 que detecta la molècula lA present en diferents tipus cel.lulars marca un gran nombre de cè1.lules a nivell de l'enzima sinovial dels animals control, i en els animals artrítics aquest nombre és molt elevat.
Com a primer estudi d'immunoteràpia i per tal d'analitzar la implicació dels limfòcits T gamma/detla en l'AA, van portar a terme diferents protocols terapèutics amb un AcMo dirigit contra el TCR-gamma/delta de rata, l'AcMo V65. Es van desenvolupar diferents protocols d'administració d'aquest anticòs: un tractament preventiu, realitzat a animals nounats des del moment del naixement i a dosis creixents durant 8 setmanes, és a dir durant tot el període previ a la inducció de l'AA; i 2 tractaments curatius. Un dels protocols va consistir en administrar els anticossos els dies 12, 15 i l8, és a dir, començant abans del màxim d'inflamació articular i l'altre protocol, en el qual es van assajar tres dosis diferents de l'anticòs, es va iniciar durant el màxim d'inflamació, és a dir el dia 15. En els dos tractaments curatius. es va realitzar un tractament paral.lel amb l'AcMo R73, dirigit contra el TCR-alfa/beta, com a control positiu del tractament.
En tractar amb l'AcMo V65 només es van observar algunes cèl.lules gamma/delta amb una expressió normal del seu TCR a nivell de sang perifèrica, ganglis limfàtics poplitis i mesentèrics. El que apareix és una població de limfòcits amb una expressió antigènica disminuïda de les molècules de TCR gamma/delta i de CD3 en la seva superfície. Aquest fet indica que l'AcMo V65 va produir la down-regulation del receptor i també la comodulació de la molecula CD3. Ara bé, el percentatge d'aquesta subpoblació amb el TCR modulat era inferior al percentatge de Iimfòcits T gamma/delta detectats abans del tractament, indicant que alguns limfòcits T van perdre totalment l'expressió del TCR o que es van depleccionar. El pretractament amb V65 des del naixement, que va provocar que aquests animals no tinguessin en cap moment Iimfòcits T gamma/delta amb expressió normal del seu TCR, no va aconseguir prevenir el desenvolupament de la patologia i els animals van seguir el mateix curs inflamatori que els animals artrítics control. El tractament curatiu amb l'AcMo V65, iniciat abans del màxim d'inflamació no va aconseguir modificar el volum articular respecte al grup artrític control d'isotip i el mateix va succeir amb la VSG. En canvi, l'AcMo R73, anti-TCR-alfa/beta, sí que mostra un efecte beneficiós, disminuint tant el volum articular com la VSG durant el tractament. El tractament curatiu iniciat durant el màxim d'inflamació tampoc va aconseguir modificar els paràmetres inflamatoris ni la VSG propis de les rates artrítiques, en cap de les dosis assajades.
Tot i la manca d'efecte curatiu de l'AcMo V6S observada en les variables estudiades quan el tractament es va iniciar abans del màxim d'ínflamació, es va observar un grau de destrucció articular significativament superior a l'observat en les rates artrítiques control en fases tardanes de la patologia. Aquest fet indica un paper protector fase-depenent dels limfòcits T gamma/delta a l'AA.
Després de descartar la intervenció directa dels limfòcits T gamma/delta en la patogènesi del procés artrític experimental, es va centrar l'atenció cap als limfòcits T alfa/beta, concretament cap a la població limfocítica CD4+ i la CD8+. Per estudiar la implicació d'aquestes dues poblacions limfocítiques en el desenvolupament de l'artritis, es va realitzar una immunoteràpia durant el període de latència, emprant l'AcMo anti-CD4 W3/25, a dosi de 3 mg, l'AcMo anti-CD8 OX8 a dosi d'1 mg i ambdós AcMo conjuntament.
Durant el tractament amb els AcMo W3/25 i OX8 es van estudiar també els seus efectes a nivell cel.lular per citometria de flux. L'administració de l'AcMo anti-CD4 W3/25 va produir la down-regulation dels limfòcits T CD4+, mentre que l'administració de l'AcMo OX8 va produir la deplecció dels limfòcits T CD8+ de sang perifèrica. L'administració de l'AcMo anti-CD4 W3/25 durant el període de latència administrat sol o conjuntament amb l'AcMo OX8, va inhibir el desenvolupament del procés inflamatori de l'AA, fins i tot després d'una segona inducció de la patologia, fet que confirma el paper essencial dels limfòcits T CD4+ en la patogènesi de l'AA. En canvi, l'administració de l'AcMo anti-CD8 no va modificar el curs de l'artritis, seguint els animals tractats amb aquest AcMo un curs similar al grup artrític control, la qual cosa indica que els limfòcits T CD8+ no intervenen directament ni exerceixen un paper regulador sobre els limfòcits T CD4+ en la patogènesi de l'AA.
Com a últim protocol terapèutic i amb el fi de conèixer la implicació dels limfòcits T CD4+ i els CD8+ en la perpetuació de l'AA, es va realitzar una immunoteràpia amb els mateixos AcMo que en l'estudi anterior però iniciant la teràpia el dia 14 postinducció. un cop l'artritis ja està establerta. En aquest estudi es va disposar també d'un grup tractat amb W3/25, un grup tractat amb OX8 i un grup tractat amb ambdós AcMo conjuntament.
El tractament amb l'AcMo OX8 no va aconseguir modificar el procés inflamatori ja existent. D'altra banda, el tractament amb W3/25 sol o conjuntament amb l'anticòs OX8 va ser capaç de revertir el procés inflamatori, fet que indica una implicació directa dels limfòcits T CD4+ en la perpetuació de l'AA. Aquest efecte, però, va ser transitori, ja que va desaparèixer després de 6 dosis. Aquest fet es pot atribuir al desenvolupament d'anticossos contra les 1g de ratolí administrades. que es van detectar en els animals tractats amb W3/25. A l'avaluar els nivells d'anticossos anti micobacteri desenvolupats pels diferents grups de l'estudi, cal destacar que ¡'administració de l'AcMo OX8 administrat sol va produir nivells 4 vegades superiors al dels altres grups i que van ser elevats durant tot l'estudi, el que suggereix que els limfòcits T CDS5+ tenen un efecte regulador sobre les cèl.lules responsables de la resposta humoral dirigida contra el micobacteri.
En resum, en aquest treball s'ha demostrat la implicació dels limfòcits T CD4+ o col.laboradors no només en la fase de desenvolupament del procés artrític. sinó també en el procés de cronificació, fet que permet considerar els limfòcits T CD4+ com a possibles dianes d'un tractament en l'AR humana. Cal tenir en compte, però, que aquest tractament s'ha de realitzar de forma contínua i amb molècules que no estimulin una resposta immunitària. A més a més, s'ha demostrat que els limfòcits T gamma/delta juguen un paper secundari en el desenvolupament de l'AA i que aquest paper és més aviat protector, modulant l'acció exercida per altres tipus cel.lulars en una determinada fase de la patologia. D'altra banda, els limtòcits T CD8+ no estan implicats en el desenvolupament de l'artritis, ni tan sols com a moduladors de l'acció dels limtòcits T CD4+ artritogènics. Per últim, malgrat la rellevància dels limfòcits T col.laboradors en el procés artrític, la presència d'aquestes cèl.lules a nivell inflamatori local és mínima, suggerint un efecte regulat majoritàriament per citocines des dels òrgans limfoides.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint chronic inflammation, associated with synovitis and erosion of cartilage and bone. Adjuvant arthritis (AA) is an experimental autoimmune disease in rats which shares certain clinical and immunological features with RA. Although the pathogenesis of AA is unknown, a strong T lymphocyte dependence has been described.
The objectives of the present work were to identify cell populations present on inflamed tissue from arthritic rats and to determine the role of gamma/delta, CD4 and CDS T lymphocytes on the development and the perpetuation of adjuvant arthritis. For these purposes, we performed different immunotherapy protocols using monoclonal antibodies (MoAb) directed against alpha/beta, gamma/delta, CD4 and CD8 T cells.
The immunohistochemical analysis of synovia revealed that only a few CD5+ cells appeared on some arthritic tissues. No CD5+ cell appeared on healthy lissues. Arthritic tissues showed a higher number of CD5+, CD4+ and Ia+ cells than healthy tissues.
Immunotherapy with an anti-gamma/delta-TCR MoAb was applied according to a preventive and to a pre-peak and a late therapeutic schedule. Although all protocols down-regulated gamma/delta-TCR expression in peripheral blood and lymph nodes cells, none influenced clinical parameters of AA. If rats were treated before the clinical peak of AA, joint destruction was more severe than in vehicle-treated rats, suggesting a stage-dependent protective role of gamma/delta T cells in AA.
To study the pathogenic role of CD4 and CD8 T cells on arthritis, an immunotherapy using an anti-CD4 MoAb, W3/25, an anti-CDS MoAb, OX8 or both together was performed during the latency period of AA. W3/25 (which was found to be non-depleting) alone or in combination with OX8 prevented the inflammatory process of AA. To ascertain if any of the last MoAb could reverse AA, an immunotherapy beginning on day 14 postinduction was applied. During treatment with W3/25, a strong amelioration of inflammatory signals occurred. This study indicates that CD4+ cells play an important role both on the initiation and the perpetuation of AA, while CD8+ cells do not appear relevant for the development of the disease.
Beyer, Kathryn. "Depression in patients with cancer receiving adjuvant chemotherapy". University of Southern Queensland, Faculty of Sciences, 2009. http://eprints.usq.edu.au/archive/00006177/.
Texto completoPaquette, François. "Étude des interactions ciment-adjuvant par calorimétrie d'immersion". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape7/PQDD_0016/MQ56950.pdf.
Texto completoGoss, Paul E., James N. Ingle, Kathleen I. Pritchard, Nicholas J. Robert, Hyman Muss, Julie Gralow, Karen Gelmon et al. "Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years". MASSACHUSETTS MEDICAL SOC, 2016. http://hdl.handle.net/10150/621478.
Texto completoPopeliuk, N. O. y O.-M. V. Popeliuk. "The pyloroduodenal pathology. Optimization of the adjuvant therapy". Thesis, БДМУ, 2017. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/17143.
Texto completoPaquette, François. "Étude des interactions ciment-adjuvant par calorimétrie d'immersion". Sherbrooke : Université de Sherbrooke, 1999.
Buscar texto completoDalziel, Catherine Ellen. "The molecular basis of adjuvant activity of pneumolysin". Thesis, University of Glasgow, 2014. http://theses.gla.ac.uk/5405/.
Texto completoShahum, Éliane. "Les mécanismes cellulaires du pouvoir adjuvant des liposomes". Thèse, Université du Québec à Trois-Rivières, 1992. http://depot-e.uqtr.ca/6793/1/000597798.pdf.
Texto completoLal, Ravin. "The Effects of Anthracycline/Taxane Adjuvant Chemotherapy and Resistance Exercise on Body Composition, Muscle Strength, Quality of Life and Fatigue in Breast Cancer Survivors". Thesis, Griffith University, 2016. http://hdl.handle.net/10072/365738.
Texto completoThesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Allied Health
Griffith Health
Full Text
Neto, Francisco Mariano. "Aplicabilidade de sílica mesoporosa ordenada como adjuvante imunológico". Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/43/43134/tde-17122008-091941/.
Texto completoThis work consisted of an evaluation, from a physical standpoint, of the applicability of SB.4-15 type ordered rnesoporous silica as an inmunological adjuvant. The method of preparation and reproducibility of the material properties were initially studied. Those conditions are necessary to synthesize large quantities of the material (N 100g). Vacuum calcination, whem compared to the process executed in A5 and air, results in a better ordered mesoporous structure. For biological applications, the potential to encapsulate antigens in the material was analyzed through studies of incorporation of Bovine Serum Albumin (BSA) and vaccine for Hepatitis A. A successful incorporation of BSA in the silica was observed, with that protein being lodged inside the porous structure. A similar result was obtained for the vaccine for Hepatitis A. The most efficient incorporation process was determined by keeping the solution at rest and drying it through evaporation. The applicability of silica as an immunological adjuvant for animal use was evaluated through PIXE analyses of the silicon accumulation in mice\'s organs. Silica was administrated to Swiss mice through oral and intramuscular ways and the silicon content of different organs was compared to the figures of the control group. The silica´s presence was detected on certain organs, and it was completely eliminated after 70 days. Besides that, toxicological studies accomplished at the Butantan Institute showed that the silica is efficient for inductíon of humoral response and it is non-toxic.
Garcia, Paulo Ricardo de Abreu Furtado. "Síntese e análise da sílica mesoporosa SBA-15 para incorporação de moléculas". Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/43/43134/tde-27042015-084615/.
Texto completoIn this work we studied the encapsulation of proteins with different molecular weights into SBA-15 ordered mesoporous silica to evaluate its application as immunological adjuvant. Hence, the IgG protein (150 kDa) and BSA (66.5 kDa) were incorporated into the mesoporous silica with expanded pores. First we studied the expansion of the pores using a structure swelling agent in the synthesis process, by preparing samples with different amounts of triisopropylbenzene (TiPB). Results of Nitrogen Adsorption Isotherm (NAI) and Small Angle X-Ray Scattering (SAXS) showed an increase in average pore diameter of the order of 23% and a more disordered pore network. To provide an estimate of the size of proteins, SAXS measurements were performed and indicated that both have dimensions that allow its incorporation in the pores of SBA-15. These samples were used for the incorporation of IgG and BSA proteins in phosphate buffered saline (PBS) solution. The results indicated a filling of the micropores by PBS solution larger than 95%. Concerning the filling of mesopores, we observed a larger variation in pore volume and surface area for the material with highest average pore diameter, reaching values around 80% and 90%, respectively. There was no significant difference in these percentages between the incorporation of the two proteins, indicating that the proteins could be encapsulated in the silica macroporosity, blocking the entry of mesopores. A theoretical model was used to analyze the SAXS measurements and it confirmed the filling of micropores and the presence of protein in the silica mesopores. Using the analytical technique \"Particle-Induced X-ray Emission\"(PIXE), the silicon content in mice feces was evaluated as a function of time, in order to analyze the release of silica from the organism of the mice. We observed that after the first silica administration the isogenic mice inoculated by oral administration released a similar amount of silicon compared with the amount released by the isogenic control mice, which received only PBS solution. After the second oral administration, the mice inoculated with silica released a higher amount of silicon than the control mice, due to the death of macrophages and other cells that act on the immune response, indicating the elimination of silicon by the organism. A parallel study about quality control was performed on SBA-15 samples prepared by Cristália Produtos Químicos Farmacêuticos Ltda., to ensure the reproducibility of this material which will be used commercially for the formulation of an oral vaccine against hepatitis B, produced by the Butantan Institute. The results showed reproducible textural properties of the samples produced by the Cristália pharmaceutical industry.
Mansfield, Richard J. R. "Adjuvant photodynamic therapy following endovascular intervention : mechanisms and effects". Thesis, University of Leeds, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.416844.
Texto completoBuijs, Ciska. "Long-term side effects of adjuvant breast cancer treatment". [S.l. : Groningen : s.n. ; University Library of Groningen] [Host], 2008. http://irs.ub.rug.nl/ppn/306087480.
Texto completoAjdukiewicz, Katherine M. B. "Glycerol adjuvant therapy in adult bacterial meningitis in Malawi". Thesis, University of Liverpool, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.632134.
Texto completoMan, Monica y Marijana Savic. "Kvinnors upplevelser av adjuvant cytostatikabehandling vid bröstcancer : en litteraturstudie". Thesis, Högskolan Kristianstad, Sektionen för hälsa och samhälle, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-13532.
Texto completoBackground: Adjuvant chemotherapy is used to treat breast cancer after the removal of the tumour. Side effects may occur since chemotherapy affects all of the body cells. The nurse should be able to provide good care, to do so it requires that she/he takes part of patients’ experiences of adjuvant chemotherapy. Aim: The aim was to describe women’s experiences of adjuvant chemotherapy for breast cancer Method: A literature review based on 13 scientific articles with qualitative approach was executed. Results: The result consisted of three main categories: experiencing a changed body, experiencing a changed mind and perceived impact on social life. It was revealed that women experienced both physical and psychological side effects and they had a great impact on their social life. Conclusion: The conclusion shows the importance of the nurse’s support in form of information and care.
Carabine, Una A. "The value of clonidine as an adjuvant to anaesthesia". Thesis, Queen's University Belfast, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.334478.
Texto completoNordenstorm, Petter y Amanda Garpebring. "Upplevelser av träning under adjuvant cancerbehandling : En kvalitativ intervjustudie". Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-312550.
Texto completoABSTRACT Background: According to the Regional Cancer Centre's national treatment plan for cancer rehabilitation all patients with a cancer diagnosis are recommended to try to move as much as a healthy person. Even so it happens that people with cancer reduces their physical activity. Therefore, it is important to get a deeper understanding of how these patients experience training during their treatment. Aim: Describe how cancer patients experience exercise during treatment and the factors that affect patients’ exercise (self-care) during treatment. Method: A qualitative interview study. Eleven interviews from a pilot study in the Phys-Can project were analyzed using qualitative content analysis. Result: Support from professionals, people in a similar situation, relatives and support from her/himself participants experienced as important to carry out their training. Practical factors as time to exercise, the ability to get to the training venue and how they experienced the venue the participants affected how their training was perceived. The participants have experienced that exercise affects mental and physical factors in them mostly for the better. The traning has also affectes som of the participants’ experince of their disease. Conclusion: The participants in this study have experienced various forms of support that has been experienced as important to be able to perform the exercise as self-care. The practical conditions around the training could both complicate or simplify training. Participants also felt that the training has affected their mental and physical health, usually for the better. It is important to be able to see each individual's ability to perform self-care, and then align support so that exercise becomes as good as possible.
Karlsson, Sandra. "Infektioner i samband med adjuvant cytostatikabehandling av invasiv bröstcancer". Thesis, Örebro universitet, Institutionen för medicinska vetenskaper, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-55054.
Texto completoBachuk-Ponych, N. V. "Adjuvant therapy of meteosensivity patients with ischemic heart disease". Thesis, БДМУ, 2022. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/19560.
Texto completoMensah, Priscilla Darling Naa-Ahimah. "Physicochemical studies of a novel adjuvant and conjugate vaccines". Doctoral thesis, University of Cape Town, 2010. http://hdl.handle.net/11427/6335.
Texto completoIncludes bibliographical references.
South African children currently receive vaccines against Diphtheria, Tetanus, Pertussis (administered as DTP), Hepatitis B (HBV) and Haemophilus influenzae type b (Hib) at 6, 10 and 14 weeks. The use of combination vaccines provides a means of avoiding the logistical problems and costs associated with multiple injections of these different vaccines. A local vaccine manufacturer is in the process of developing a combined tetravalent DTP-HBV as well as a liquid pentavalent DTP-HBV-Hib vaccine. The Hib vaccine is a glycoconjugate in which Haemophilus influenzae type b capsular polysaccharide (polyribosylribitolphosphate or PRP) is conjugated to a carrier protein. The conjugate is immunogenic in infants who have a higher risk of infection while the polysaccharide vaccine is not. The compatibility of the Hib antigenic component in the presence of the other antigens and adjuvant presents a challenge. Aluminium containing adjuvants have been the most widely used adjuvants in human vaccines. Aluminium hydroxide has been found to catalyse the hydrolysis of PRP when added to Hib conjugate vaccines. Although this can be circumvented by the use of aluminium phosphate, there is a need for new adjuvants that elicit broader immune responses. This thesis presents a study of the size, structure and composition of a locally developed experimental adjuvant called Pheroid™ by use of NMR spectroscopy and Coulter Counter. NMR analysis of Pheroid™ formulations provided a structural fingerprint for the formulations and indicated the relative proportions of the major components present, whereas their particle size distribution was profiled using a Coulter Counter. The average size distribution was similar in the formulations tested including those that had been activated using nitrous oxide. The primary focus of this thesis was the application of appropriate physicochemical procedures for evaluation of the locally manufactured Hib vaccine alone and when in combination with DTP-HBV-Hib. Investigating the stability and integrity of Hib conjugate vaccines requires determination of the total saccharide and unbound or free saccharide which is expressed as the percentage of free saccharide present. In the absence of a suitable Hib conjugate, model compounds such as human serum albumin (HSA) , meningococcal group A polysaccharide (PsA) and the derived conjugate (Mn A-IT) were used to investigate three methods of free saccharide separation: solid phase extraction (SPE), acid precipitation using deoxycholate (DOC/HCI) and ultrafiltration (UF). At physiological pH, the binding capacity was low and so the SPE method was not investigated further. For Mn A-IT the DOC/HCI method generally gave lower free saccharide values than the UF method; this was attributed to entrapment and coprecipitation of free saccharide by DOC/HCI. In contrast, washing steps in the UF method ensured good free saccharide recovery. A colorimetric assay for phosphorus and high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) were investigated for saccharide quantification in Mn A-TT vaccines. The HPAEC-PAD method for the monomer (mannosamine-6-phosphate from acid hydrolysis) permitted higher specificity and sensitivity for the free saccharide analysis compared to the phosphate assay. The DOC/HCI and UF methods were compared by their application to Mn A-TT samples subjected to an accelerated stability study.
Jawyn, Natalie. "Mechanisms of Adjuvant Induction of the Innate Immune Response". University of Akron / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=akron1302484631.
Texto completoMastrandrea, Nicholas Joseph. "Pentoxifylline As An Adjuvant Treatment In Renal Cell Carcinoma". Diss., The University of Arizona, 2014. http://hdl.handle.net/10150/337293.
Texto completoGiallourou, Natasa. "Watercress as a nutritional adjuvant treatment in breast cancer". Thesis, University of Reading, 2017. http://centaur.reading.ac.uk/76171/.
Texto completo